12/20
02:03 am
nspr
InspireMD, Inc. (NYSE: NSPR) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
InspireMD, Inc. (NYSE: NSPR) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
12/12
07:13 am
nspr
InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025 [Yahoo! Finance]
Low
Report
InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025 [Yahoo! Finance]
12/12
07:00 am
nspr
InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025
Low
Report
InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025
12/11
02:15 pm
nspr
InspireMD, Inc. (NYSE: NSPR) is now covered by analysts at Lake Street Capital. They set a "buy" rating and a $5.00 price target on the stock.
Low
Report
InspireMD, Inc. (NYSE: NSPR) is now covered by analysts at Lake Street Capital. They set a "buy" rating and a $5.00 price target on the stock.
12/9
07:09 am
nspr
InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR) [Yahoo! Finance]
Low
Report
InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR) [Yahoo! Finance]
12/9
07:00 am
nspr
InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)
Low
Report
InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)
11/26
03:06 am
nspr
InspireMD, Inc. (NYSE: NSPR) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
InspireMD, Inc. (NYSE: NSPR) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/25
04:16 pm
nspr
InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors [Yahoo! Finance]
Medium
Report
InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors [Yahoo! Finance]
11/25
04:05 pm
nspr
InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors
Low
Report
InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors
11/18
03:06 am
nspr
InspireMD, Inc. (NYSE: NSPR) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
InspireMD, Inc. (NYSE: NSPR) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/14
05:54 am
nspr
InspireMD Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$0.15 loss in 3Q 2023) [Yahoo! Finance]
Low
Report
InspireMD Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$0.15 loss in 3Q 2023) [Yahoo! Finance]
11/13
02:26 am
nspr
InspireMD Inc (NSPR) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Rising Costs and ... [Yahoo! Finance]
High
Report
InspireMD Inc (NSPR) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Rising Costs and ... [Yahoo! Finance]
11/12
07:00 am
nspr
InspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
InspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update
11/11
07:33 am
nspr
What To Expect From InspireMD Inc (NSPR) Q3 2024 Earnings [Yahoo! Finance]
Medium
Report
What To Expect From InspireMD Inc (NSPR) Q3 2024 Earnings [Yahoo! Finance]
11/10
02:02 am
nspr
InspireMD, Inc. (NYSE: NSPR) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
InspireMD, Inc. (NYSE: NSPR) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/8
05:30 pm
nspr
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/4
08:00 am
nspr
InspireMD to Report Third Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, November 12th
Low
Report
InspireMD to Report Third Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, November 12th
10/25
02:07 am
nspr
InspireMD, Inc. (NYSE: NSPR) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
InspireMD, Inc. (NYSE: NSPR) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/21
10:03 am
nspr
One InspireMD Insider Raised Stake By 13% In Previous Year [Yahoo! Finance]
Low
Report
One InspireMD Insider Raised Stake By 13% In Previous Year [Yahoo! Finance]
10/17
02:00 am
nspr
InspireMD, Inc. (NYSE: NSPR) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
InspireMD, Inc. (NYSE: NSPR) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/15
07:00 am
nspr
InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System
Medium
Report
InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System
10/10
11:11 am
nspr
InspireMD Gains FDA Premarket Approval for CGuard Prime Carotid Stent [Yahoo! Finance]
Low
Report
InspireMD Gains FDA Premarket Approval for CGuard Prime Carotid Stent [Yahoo! Finance]
10/9
02:01 am
nspr
InspireMD, Inc. (NYSE: NSPR) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
InspireMD, Inc. (NYSE: NSPR) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/7
07:00 am
nspr
InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System
Medium
Report
InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System
10/1
02:07 am
nspr
InspireMD, Inc. (NYSE: NSPR) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
InspireMD, Inc. (NYSE: NSPR) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.